Skip to main content

Neuromuscular training reduces chemotherapy-induced neuropathy

Neuromuscular training significantly reduced the onset of chemotherapy-induced peripheral neuropathy in people with cancer enrolled in the STOP trial.

Editor's Choice

Excellent response to immunotherapy in rare pancreatic cancer

Open Access Pancreatic Cancer Review

A patient with pancreatic acinar cell carcinoma responded well to treatment with pembrolizumab and was able to undergo surgery. The patient remains disease-free 6 months after surgery.

Advances in DLBCL

Diffuse large B-cell lymphoma represents nearly 30% of all cases of non-Hodgkin's lymphoma. Understand the underlying genetics, diagnostic criteria, and current and emerging therapeutic approaches. 

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Mediterranean diet linked to reduced mortality in cancer survivors

Greater adherence to a Mediterranean diet is associated with a reduced risk for all-cause and cardiovascular mortality in cancer survivors.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Lung Cancer Clinical Trial Summary

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case Studies

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Hodgkin’s lymphoma masquerading as ocular inflammation

Open Access Hodgkin Lymphoma Case Study

A 17-year-old presented with non-necrotizing scleritis, anterior uveitis, vitritis, yellowish chorioretinal lesions, papillitis, and vasculitis. Would you consider Hodgkin’s lymphoma in the differential diagnosis?

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe

Current Reviews

Treatment Options for Brain Metastases

Open Access Metastasis

Therapies for brain metastasis continue to evolve as the life expectancies for patients have continued to prolong. Novel advances include the use of improved technology for radiation delivery, surgical guidance, and response assessment, along with …

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals

Open Access Eosinophilia

Eosinophilia and hypereosinophilia (HE) are defined as an absolute eosinophil count of ≥ 0.5 × 10 9 /L and ≥ 1.5 × 10 9 /L in peripheral blood (PB), with an arbitrarily distinction into mild (< 1.5 × 10 9 /L), moderate (1.5–5 × 10 9 /L), and severe …

Tunlametinib: First Approval

Melanoma AdisInsight Report

Tunlametinib (科露平®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor being developed by Shanghai KeChow Pharma, Inc. for the treatment of solid tumours with RAS and RAF mutations, including melanoma …

Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy

Open Access Checkpoint Inhibitors Cardio-Oncology

Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer treatment, harnessing the immune system to combat malignancies by targeting checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and …

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine

CME & eLearning

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME
SPONSORED

Webinar

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK. 

Sponsored by:
  • Novartis Pharma AG
Developed by: Springer Healthcare

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

Further Reading

The impact of the COVID-19 pandemic on the performance of the Rapid Access Lung Cancer Clinic

Open Access Lung Cancer Original Article

Lung cancer is among the most common cancers diagnosed in Ireland and indeed globally [ 1 , 2 ]. With more than 2 million cases worldwide and 2700 cases in Ireland diagnosed annually, lung cancer is also the leading cause of cancer-related deaths [ …1

Treatment Options for Brain Metastases

Open Access Metastasis

Therapies for brain metastasis continue to evolve as the life expectancies for patients have continued to prolong. Novel advances include the use of improved technology for radiation delivery, surgical guidance, and response assessment, along with …

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals

Open Access Eosinophilia

Eosinophilia and hypereosinophilia (HE) are defined as an absolute eosinophil count of ≥ 0.5 × 10 9 /L and ≥ 1.5 × 10 9 /L in peripheral blood (PB), with an arbitrarily distinction into mild (< 1.5 × 10 9 /L), moderate (1.5–5 × 10 9 /L), and severe …

Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy

Open Access Checkpoint Inhibitors Cardio-Oncology

Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer treatment, harnessing the immune system to combat malignancies by targeting checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and …